JP2005533082A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005533082A5 JP2005533082A5 JP2004516732A JP2004516732A JP2005533082A5 JP 2005533082 A5 JP2005533082 A5 JP 2005533082A5 JP 2004516732 A JP2004516732 A JP 2004516732A JP 2004516732 A JP2004516732 A JP 2004516732A JP 2005533082 A5 JP2005533082 A5 JP 2005533082A5
- Authority
- JP
- Japan
- Prior art keywords
- gaba
- halogen
- antagonist
- general formula
- nitrile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000681 4 aminobutyric acid C receptor blocking agent Substances 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical group 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 150000002431 hydrogen Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 150000002825 nitriles Chemical group 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- 208000001491 Myopia Diseases 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 230000004379 myopia Effects 0.000 claims 2
- 108060003377 GABA-B receptor family Proteins 0.000 claims 1
- 102000017934 GABA-B receptor family Human genes 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 239000003412 4 aminobutyric acid B receptor blocking agent Substances 0.000 description 3
- QVUUPQCCYOPHFY-UHFFFAOYSA-N 3-aminopropyl(hexyl)phosphinic acid Chemical compound CCCCCCP(O)(=O)CCCN QVUUPQCCYOPHFY-UHFFFAOYSA-N 0.000 description 1
- GSZQTIFGANBTNF-UHFFFAOYSA-N 3-aminopropylphosphonic acid Chemical compound NCCCP(O)(O)=O GSZQTIFGANBTNF-UHFFFAOYSA-N 0.000 description 1
- WBSMZVIMANOCNX-UHFFFAOYSA-N 3-azaniumyl-2-(4-chlorophenyl)-2-hydroxypropane-1-sulfonate Chemical compound OS(=O)(=O)CC(O)(CN)C1=CC=C(Cl)C=C1 WBSMZVIMANOCNX-UHFFFAOYSA-N 0.000 description 1
- JJMDCOVWQOJGCB-UHFFFAOYSA-N 5-aminopentanoic acid zwitterion Chemical compound [NH3+]CCCCC([O-])=O JJMDCOVWQOJGCB-UHFFFAOYSA-N 0.000 description 1
- QIIVUOWTHWIXFO-UHFFFAOYSA-N CGP-35348 Chemical compound CCOC(OCC)P(O)(=O)CCCN QIIVUOWTHWIXFO-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
Description
US5,385,939(Laties & Stone)は、GABA−Bアンタゴニストである2−ヒドロキシ−サクロフェンを有効量で投与することを含む、動物の眼の軸方向増殖を抑制する方法を記載している。ファクロフェン、5−アミノ吉草酸、3−アミノプロピル(ジエトキシメチル)ホスフィン酸、3−アミノプロピル(n−ヘキシル)ホスフィン酸および3−アミノプロピルホスホン酸のような他のGABA−B−アンタゴニストが、適当なGABA−B−アンタゴニストとして特記されている。
Claims (10)
- 近視の処置のための医薬の製造における、GABA−Cレセプターアンタゴニストの使用。
- 該GABA−CレセプターアンタゴニストがGABA−Bレセプターに不活性である、請求項1−2のいずれかに記載の使用。
- 近視の処置が、眼の異常な軸方向増殖の抑制を意味する、請求項1に記載の使用。
- 該GABA−Cアンタゴニストをヒトの眼に局所投与する、請求項1−4のいずれかに記載の使用。
- 活性成分としてGABA−C−アンタゴニストを含む、近視処置剤。
- 該GABA−Cレセプターアンタゴニストを静脈内に、経腸的に、または局所的に投与する、請求項6記載の処置剤。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02014412 | 2002-06-28 | ||
PCT/EP2003/006850 WO2004002399A2 (en) | 2002-06-28 | 2003-06-27 | Use of gaba-c receptor antagonists for the treatment of myopia |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005533082A JP2005533082A (ja) | 2005-11-04 |
JP2005533082A5 true JP2005533082A5 (ja) | 2006-08-31 |
Family
ID=29797147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004516732A Pending JP2005533082A (ja) | 2002-06-28 | 2003-06-27 | 近視の治療のためのgaba−cレセプターアンタゴニストの使用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20060142249A1 (ja) |
EP (1) | EP1526858A2 (ja) |
JP (1) | JP2005533082A (ja) |
AU (1) | AU2003245995A1 (ja) |
WO (1) | WO2004002399A2 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI793072B (zh) | 2016-04-11 | 2023-02-21 | 坎培拉大學 | 組成物及方法之應用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5385939A (en) * | 1993-04-30 | 1995-01-31 | The Trustees Of The University Of Pennsylvania | GABA-ergic modulation of eye growth |
US5627169A (en) * | 1994-07-20 | 1997-05-06 | The Regents Of The University Of California | Selective antagonists for GABArho receptor |
WO1998028313A1 (en) * | 1996-12-24 | 1998-07-02 | Novartis Ag | (thio)morpholine-substituted carboxylic and phosphinic acids |
DE69827635T2 (de) * | 1997-06-23 | 2006-02-02 | Neuro Therapeutics Ltd., Toorak | Gaba-c-rezeptor-antagonisten zur stimulation des erinnerungsvermögens |
US20060264508A1 (en) * | 2001-10-16 | 2006-11-23 | Stone Richard A | Modulation of ocular growth and myopia by gaba drugs |
-
2003
- 2003-06-27 WO PCT/EP2003/006850 patent/WO2004002399A2/en active Application Filing
- 2003-06-27 JP JP2004516732A patent/JP2005533082A/ja active Pending
- 2003-06-27 EP EP03738095A patent/EP1526858A2/en not_active Withdrawn
- 2003-06-27 US US10/516,246 patent/US20060142249A1/en not_active Abandoned
- 2003-06-27 AU AU2003245995A patent/AU2003245995A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2017537949A5 (ja) | ||
ES2613931T3 (es) | Compuestos peptídicos para tratar el estado epiléptico refractario | |
EP1857457A3 (en) | Benzimidazole derivative and its use as AII receptor antagonist | |
ATE375341T1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
JP2008500390A5 (ja) | ||
JP2009533356A5 (ja) | ||
JP2019515884A5 (ja) | ||
JP2006507220A5 (ja) | ||
JP2009504763A5 (ja) | ||
CY1109242T1 (el) | Θεραπευτικοι παραγοντες χρησιμοι για θεραπεια πονου | |
WO2005056524A3 (en) | Therapeutic agents useful for treating pain | |
JP2015025011A5 (ja) | ||
RU2011111117A (ru) | Лечение аутоиммунных заболеваний | |
JP2015535247A5 (ja) | ||
CA2608163A1 (en) | Hydralazine compositions and methods | |
JP2008540528A5 (ja) | ||
JP2012513471A5 (ja) | ||
RU2009111387A (ru) | Фармацевтические композиции для лечения грибковых инфекций | |
JP2019531286A5 (ja) | ||
RU99121654A (ru) | Средства для предотвращения или лечения болезней, связанных с чрезмерной пролиферацией эпителиальных пигментных клеток сетчатки | |
JP2005526773A5 (ja) | ||
JP2018525447A5 (ja) | ||
RU2010151143A (ru) | Замещенные хиназолины | |
JP2005533082A5 (ja) | ||
JP2012504584A5 (ja) |